XBiotech Inc.(XBIT)Earnings, Financials & Key Ratios
XBIT•NASDAQ
$2.55
$78M mkt cap·Price updated May 6, 2026
AboutXBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.Show more
- Revenue$0
- EBITDA-$41M-13.9%
- Net Income-$39M-56.9%
- EPS (Diluted)-1.26-55.6%
- ROE-19.21%-79.6%
- ROIC-164.77%-198.5%
- Debt/Equity0.06
- Interest Coverage-52.63
XBIT Key Insights
XBiotech Inc. (XBIT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.4x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
XBIT Price & Volume
XBiotech Inc. (XBIT) stock price & volume — 10-year historical chart
Loading chart...
XBIT Growth Metrics
XBiotech Inc. (XBIT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM10.72%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM10.5%
Return on Capital
10 Years-27.97%
5 Years-12.4%
3 Years-16.88%
Last Year-21%
XBIT Peer Comparison
XBiotech Inc. (XBIT) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 ARQT | 3.02B | 24.17 | -185.92 | 91.34% | -0.57% | -1.41% | 0.03 | |
 DAWN | 2.22B | 21.53 | -20.70 | 20.6% | -67.85% | -23.43% | 0.01 | |
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 NUVL | 6.92B | 104.26 | -26.53 | -45.12% | ||||
 REGN | 74.89B | 720.78 | 17.38 | 0.99% | 29.65% | 14.32% | 0.09 | |
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% |
Compare XBIT vs Peers
XBiotech Inc. (XBIT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XBIT Income Statement
XBiotech Inc. (XBIT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 44M | 18.39M | 4.01M | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | -58.19% | -78.2% | -100% | - | - |
| Cost of Goods Sold | 698K | 1.48M | 2.43M | 2.36M | 34.55M | 5.82M | 651K | 0 | 0 | 427K |
| COGS % of Revenue | - | - | - | - | 78.52% | 31.64% | 16.23% | - | - | - |
| Gross Profit | -698K▲ 0% | -1.48M▼ 112.6% | -2.43M▼ 63.9% | -2.36M▲ 3.0% | 9.45M▲ 500.2% | 12.57M▲ 33.1% | 3.36M▼ 73.3% | 0▼ 100.0% | 0▲ 0% | -427K▲ 0% |
| Gross Margin % | - | - | - | - | 21.48% | 68.36% | 83.77% | - | - | - |
| Gross Profit Growth % | 0.14% | -112.61% | -63.95% | 2.96% | 500.21% | 33.07% | -73.29% | -100% | - | - |
| Operating Expenses | 52.76M | 34.06M | 20.99M | 28.87M | 27.73M | 37.66M | 37.85M | 37.51M | 42.47M | 34.25M |
| OpEx % of Revenue | - | - | - | - | 63.02% | 204.72% | 943.87% | - | - | - |
| Selling, General & Admin | 10.28M | 7.63M | 5.27M | 4.78M | 18.2M | 9.39M | 6.3M | 4.66M | 4.71M | 4.4M |
| SG&A % of Revenue | - | - | - | - | 41.36% | 51.04% | 157.23% | - | - | - |
| Research & Development | 42.49M | 26.42M | 15.72M | 24.09M | 9.53M | 28.27M | 31.54M | 32.85M | 37.76M | 29.86M |
| R&D % of Revenue | - | - | - | - | 21.65% | 153.68% | 786.63% | - | - | - |
| Other Operating Expenses | 0 | 0 | 4K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -52.76M▲ 0% | -34.06M▲ 35.4% | -20.99M▲ 38.4% | -31.23M▼ 48.8% | -18.28M▲ 41.5% | -25.08M▼ 37.2% | -34.49M▼ 37.5% | -37.51M▼ 8.8% | -42.47M▼ 13.2% | -34.68M▲ 0% |
| Operating Margin % | - | - | - | - | -41.54% | -136.36% | -860.1% | - | - | - |
| Operating Income Growth % | -40.66% | 35.45% | 38.36% | -48.77% | 41.48% | -37.24% | -37.51% | -8.76% | -13.23% | - |
| EBITDA | -52.06M | -32.58M | -18.56M | -28.87M | -16.04M | -22.43M | -31.88M | -35.77M | -40.73M | -32.93M |
| EBITDA Margin % | - | - | - | - | -36.45% | -121.96% | -794.91% | - | - | - |
| EBITDA Growth % | -41.44% | 37.43% | 43.02% | -55.55% | 44.45% | -39.88% | -42.09% | -12.2% | -13.87% | 18.82% |
| D&A (Non-Cash Add-back) | 698K | 1.48M | 2.43M | 2.36M | 2.24M | 2.65M | 2.61M | 1.74M | 1.75M | 1.75M |
| EBIT | -52.76M | -34.06M | -21.14M | 718.45M | -18.28M | -25.08M | -34.49M | -24.31M | -37.76M | -28.75M |
| Net Interest Income | 0 | 0 | 0 | 564K | 2.46M | 467K | 3.82M | 10.42M | 9.01M | 6.26M |
| Interest Income | 49K | 354K | 400K | 564K | 2.46M | 467K | 3.82M | 10.42M | 9.81M | 6.56M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 807K | 292K |
| Other Income/Expense | 2K | 909K | -144K | 749.69M | 5.45M | -376K | 902K | 13.2M | 3.91M | 5.64M |
| Pretax Income | -52.76M▲ 0% | -33.15M▲ 37.2% | -21.14M▲ 36.2% | 718.45M▲ 3498.9% | -12.83M▼ 101.8% | -25.46M▼ 98.5% | -33.59M▼ 31.9% | -24.31M▲ 27.6% | -38.56M▼ 58.6% | -29.04M▲ 0% |
| Pretax Margin % | - | - | - | - | -29.15% | -138.4% | -837.61% | - | - | - |
| Income Tax | -2K | 0 | -144K | 49.82M | -1.61M | -8.04M | -688K | 244K | -32K | 118K |
| Effective Tax Rate % | 0% | 0% | 0.68% | 6.93% | 12.52% | 31.6% | 2.05% | -1% | 0.08% | -0.41% |
| Net Income | -52.76M▲ 0% | -33.15M▲ 37.2% | -21.14M▲ 36.2% | 668.63M▲ 3263.2% | -11.22M▼ 101.7% | -17.41M▼ 55.2% | -32.9M▼ 88.9% | -24.56M▲ 25.4% | -38.53M▼ 56.9% | -29.16M▲ 0% |
| Net Margin % | - | - | - | - | -25.5% | -94.67% | -820.45% | - | - | - |
| Net Income Growth % | -40.76% | 37.17% | 36.24% | 3263.16% | -101.68% | -55.19% | -88.93% | 25.36% | -56.9% | 10.72% |
| Net Income (Continuing) | -52.76M | -33.15M | -21.14M | 668.63M | -11.22M | -17.41M | -32.9M | -24.56M | -38.53M | -29.16M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.63▲ 0% | -0.95▲ 41.7% | -0.59▲ 37.9% | 14.44▲ 2547.5% | -0.36▼ 102.5% | -0.58▼ 61.1% | -1.08▼ 86.2% | -0.81▲ 25.0% | -1.26▼ 55.6% | -0.96▲ 0% |
| EPS Growth % | -33.61% | 41.72% | 37.89% | 2547.46% | -102.49% | -61.11% | -86.21% | 25% | -55.56% | 10.5% |
| EPS (Basic) | -1.63 | -0.95 | -0.59 | 17.17 | -0.36 | -0.58 | -1.08 | -0.81 | -1.26 | - |
| Diluted Shares Outstanding | 32.4M | 34.88M | 35.8M | 46.32M | 30.82M | 30.04M | 30.44M | 30.44M | 30.46M | 30.49M |
| Basic Shares Outstanding | 32.4M | 34.88M | 35.8M | 38.95M | 30.82M | 30.04M | 30.44M | 30.32M | 30.46M | 30.49M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
XBIT Balance Sheet
XBiotech Inc. (XBIT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 36.93M | 33.33M | 17.02M | 716.26M | 325.88M | 246.87M | 219.84M | 201.72M | 174.57M | 148.95M |
| Cash & Short-Term Investments | 34.32M | 31.77M | 15.82M | 714.59M | 237.37M | 236.98M | 217.48M | 200.02M | 172.68M | 147.37M |
| Cash Only | 34.32M | 31.77M | 15.82M | 714.59M | 237.37M | 236.98M | 157.31M | 200.02M | 172.68M | 147.37M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 60.17M | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 4.11M | 8.95M | 1.76M | 935K | 858K | 450K |
| Days Sales Outstanding | - | - | - | - | 34.12 | 177.66 | 160.56 | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 2.61M | 1.56M | 1.19M | 1.67M | 83.81M | 0 | 601K | 760K | 1.03M | 1.13M |
| Total Non-Current Assets | 30.12M | 29.64M | 27.33M | 100.61M | 27.87M | 28.31M | 26.26M | 24.9M | 24.53M | 23.47M |
| Property, Plant & Equipment | 30.12M | 29.64M | 27.33M | 25.17M | 27.34M | 28.31M | 26.26M | 24.9M | 24.53M | 23.47M |
| Fixed Asset Turnover | - | - | - | - | 1.61x | 0.65x | 0.15x | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 75M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 75M | 0 | -1.09M | -1.66M | 0 | 0 | 0 |
| Total Assets | 67.05M▲ 0% | 62.97M▼ 6.1% | 44.34M▼ 29.6% | 816.88M▲ 1742.1% | 353.74M▼ 56.7% | 275.18M▼ 22.2% | 246.1M▼ 10.6% | 226.62M▼ 7.9% | 199.09M▼ 12.1% | 172.42M▲ 0% |
| Asset Turnover | - | - | - | - | 0.12x | 0.07x | 0.02x | - | - | 0.00x |
| Asset Growth % | -38.69% | -6.08% | -29.58% | 1742.09% | -56.7% | -22.21% | -10.57% | -7.92% | -12.14% | -67.27% |
| Total Current Liabilities | 7.96M | 2.79M | 2.94M | 60.19M | 3.98M | 3.45M | 4.07M | 6.1M | 15.11M | 3.56M |
| Accounts Payable | 4.43M | 1.73M | 1.65M | 2.15M | 2.49M | 2.07M | 2.41M | 2.52M | 2.22M | 1.04M |
| Days Payables Outstanding | 2.32K | 425.51 | 247.98 | 332.23 | 26.32 | 129.76 | 1.35K | - | - | 1.24K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.25M | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 4.5M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 521K | 0 | 0 | 53.2M | 1.05M | 904K | 1.17M | 562K | 611K | 2.52M |
| Current Ratio | 4.64x | 11.94x | 5.78x | 11.90x | 81.80x | 71.49x | 54.07x | 33.07x | 11.56x | 11.56x |
| Quick Ratio | 4.64x | 11.94x | 5.78x | 11.90x | 81.80x | 71.49x | 54.07x | 33.07x | 11.56x | 11.56x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 23K | 18K | 3K | 1.06M | 1.12M | 2.34M | 1.64M | 1.67M | 1.72M | 1.78M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 446K | 0 | 873K | 59K | 0 | 0 | 0 |
| Other Non-Current Liabilities | 23K | 18K | 3K | 1.06M | 1.12M | 1.47M | 1.58M | 1.67M | 1.72M | 7M |
| Total Liabilities | 7.99M | 2.81M | 2.95M | 61.25M | 5.11M | 5.79M | 5.7M | 7.77M | 16.82M | 5.34M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.25M | 0 |
| Net Debt | -34.32M | -31.77M | -15.82M | -714.59M | -237.37M | -236.98M | -157.31M | -200.02M | -162.43M | -147.37M |
| Debt / Equity | - | - | - | - | - | - | - | - | 0.06x | 0.06x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 4.47x |
| Interest Coverage | - | - | - | - | - | - | - | - | -52.63x | -98.45x |
| Total Equity | 59.06M▲ 0% | 60.16M▲ 1.9% | 41.4M▼ 31.2% | 755.63M▲ 1725.3% | 348.64M▼ 53.9% | 269.38M▼ 22.7% | 240.4M▼ 10.8% | 218.85M▼ 9.0% | 182.27M▼ 16.7% | 167.08M▲ 0% |
| Equity Growth % | -42.68% | 1.86% | -31.19% | 1725.28% | -53.86% | -22.73% | -10.76% | -8.97% | -16.71% | -58.28% |
| Book Value per Share | 1.82 | 1.73 | 1.16 | 16.31 | 11.31 | 8.97 | 7.90 | 7.19 | 5.98 | 5.48 |
| Total Shareholders' Equity | 59.06M | 60.16M | 41.4M | 755.63M | 348.64M | 269.38M | 240.4M | 218.85M | 182.27M | 167.08M |
| Common Stock | 242.42M | 277.49M | 279.35M | 324.81M | 249.81M | 262.26M | 267.32M | 271.15M | 273.11M | 276.56M |
| Retained Earnings | -183.41M | -216.56M | -237.7M | 430.93M | 97.57M | 5.15M | -27.75M | -52.31M | -90.84M | -109.48M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 57K | -768K | -255K | -106K | 1.27M | 1.97M | 826K | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
XBIT Cash Flow Statement
XBiotech Inc. (XBIT) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -46.02M | -33.65M | -16.54M | -18.27M | -65.15M | 69.44M | -14.82M | -18.73M | -30.96M | -30.96M |
| Operating CF Margin % | - | - | - | - | -148.08% | 377.54% | -369.68% | - | - | - |
| Operating CF Growth % | -38.15% | 26.87% | 50.85% | -10.48% | -256.59% | 206.59% | -121.35% | -26.32% | -65.36% | -9.32% |
| Net Income | -52.76M | -33.15M | -21.14M | 668.63M | -11.22M | -17.41M | -32.9M | -24.56M | -38.53M | -29.16M |
| Depreciation & Amortization | 698K | 1.48M | 2.43M | 2.36M | 2.24M | 2.65M | 2.61M | 1.74M | 1.75M | 1.75M |
| Stock-Based Compensation | 5.57M | 1.75M | 1.66M | 3.36M | 12.58M | 4.46M | 5.06M | 0 | 1.75M | 4.06M |
| Deferred Taxes | 0 | 0 | 0 | -444K | -90K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 6.97M | 401K | 6.53M | -674.56M | 90K | 0 | 2.8M | 1.37M | 5.53M | 1.96M |
| Working Capital Changes | 475K | -4.13M | 508K | -17.62M | -68.75M | 79.75M | 7.6M | 2.72M | -1.46M | -2.12M |
| Change in Receivables | 0 | 0 | 0 | 0 | -10.69M | 1.73M | 7.34M | 829K | 77K | 346K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -981K | -2.7M | -78K | 496K | -334K | -514K | 357K | 91K | -364K | -527K |
| Cash from Investing | -13.91M | -1.41M | -122K | 674.8M | -3.73M | -3.52M | -63.89M | 61.5M | -1.3M | -339K |
| Capital Expenditures | -13.91M | -1.41M | -122K | -204K | -3.73M | -3.52M | -585K | -362K | -1.3M | -339K |
| CapEx % of Revenue | - | - | - | - | 8.47% | 19.16% | 14.59% | - | - | - |
| Acquisitions | 0 | 0 | 0 | 675M | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -9.17M | 0 | 0 | 0 | 0 | 0 | 0 | 61.86M | 0 | 0 |
| Cash from Financing | 2.94M | 33.32M | 201K | 42.1M | -409.72M | -67.01M | 0 | -9K | 10.45M | -9.97M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.25M | -10M |
| Equity Issued (Net) | 1000K | 1000K | 0 | 1000K | -1000K | 0 | 0 | 5K | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | -75M | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -420M | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.14M | 703K | 201K | 4.03M | 10.28M | 8M | 0 | -14K | 200K | 33K |
| Net Change in Cash | -56.73M▲ 0% | -2.56M▲ 95.5% | -15.95M▼ 523.8% | 698.77M▲ 4482.4% | -477.23M▼ 168.3% | -383K▲ 99.9% | -79.68M▼ 20703.4% | 42.72M▲ 153.6% | -27.35M▼ 164.0% | -35.75M▲ 0% |
| Free Cash Flow | -59.93M▲ 0% | -35.05M▲ 41.5% | -16.66M▲ 52.5% | -18.47M▼ 10.9% | -68.88M▼ 272.8% | 65.92M▲ 195.7% | -15.41M▼ 123.4% | -19.09M▼ 23.9% | -32.27M▼ 69.1% | -23.85M▲ 0% |
| FCF Margin % | - | - | - | - | -156.55% | 358.38% | -384.26% | - | - | - |
| FCF Growth % | -37.14% | 41.51% | 52.48% | -10.9% | -272.83% | 195.71% | -123.38% | -23.87% | -69.05% | 18.31% |
| FCF per Share | -1.85 | -1.01 | -0.47 | -0.40 | -2.23 | 2.19 | -0.51 | -0.63 | -1.06 | -1.06 |
| FCF Conversion (FCF/Net Income) | 0.87x | 1.02x | 0.78x | -0.03x | 5.81x | -3.99x | 0.45x | 0.76x | 0.80x | 0.82x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 400K | 486K |
| Taxes Paid | 0 | 0 | 0 | 0 | 54.09M | 0 | 0 | 0 | 85K | 0 |
XBIT Key Ratios
XBiotech Inc. (XBIT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -65.09% | -55.61% | -41.63% | 167.78% | -2.03% | -5.64% | -12.91% | -10.69% | -19.21% | -17.45% |
| Return on Invested Capital (ROIC) | -215.42% | -96.15% | -58.35% | -70.33% | -18% | -26.19% | -44.79% | -55.21% | -164.77% | -164.77% |
| Gross Margin | - | - | - | - | 21.48% | 68.36% | 83.77% | - | - | - |
| Net Margin | - | - | - | - | -25.5% | -94.67% | -820.45% | - | - | - |
| Debt / Equity | - | - | - | - | - | - | - | - | 0.06x | 0.06x |
| Interest Coverage | - | - | - | - | - | - | - | - | -52.63x | -98.45x |
| FCF Conversion | 0.87x | 1.02x | 0.78x | -0.03x | 5.81x | -3.99x | 0.45x | 0.76x | 0.80x | 0.82x |
| Revenue Growth | - | - | - | - | - | -58.19% | -78.2% | -100% | - | - |
XBIT Frequently Asked Questions
XBiotech Inc. (XBIT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
XBiotech Inc. (XBIT) grew revenue by 0.0% over the past year. Growth has been modest.
XBiotech Inc. (XBIT) reported a net loss of $29.2M for fiscal year 2024.
Dividend & Returns
XBiotech Inc. (XBIT) has a return on equity (ROE) of -19.2%. Negative ROE indicates the company is unprofitable.
XBiotech Inc. (XBIT) had negative free cash flow of $23.8M in fiscal year 2024, likely due to heavy capital investments.
Explore More XBIT
XBiotech Inc. (XBIT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates